Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines regulation and law

Government publishes additional no-deal Brexit medicines regulation guidance

Ian Hudson, chief executive officer of the Medicines and Healthcare products Regulatory Agency

Source: Medicines and Healthcare products Regulatory Agency

Ian Hudson, chief executive officer of the Medicines and Healthcare products Regulatory Agency, said it had prepared a “robust plan” for Brexit

More information on how medicines, medical devices and clinical trials would be regulated following a no-deal Brexit has been issued by the Department of Health and Social Care.

The updated guidance, released following a public consultation led by the Medicines and Healthcare products Regulatory Agency (MHRA), sets out the proposed arrangements for regulation if the UK leaves the EU on 29 March 2019 with no deal in place.

Following the consultation, changes were made in some areas, such as allowing all existing holders of UK wholesale authorisations to purchase medicines that have been Qualified Person-certified in the EU/EEA.

Arrangements for medical devices include ongoing legal recognition of CE-certified devices from a notified body based in the UK or the EU, allowing them to be placed on the UK market. The MHRA’s registration system will also be expanded to all classes of medical device.

Clinical trials will continue to recognise existing approvals, meaning that there will be no need to re-apply. Future trials will require the sponsor or legal representative of the clinical trial to be in the UK or a country on an approved country list, which would initially include EU and EEA countries.

The MHRA noted that the majority of responses received were supportive of the consultation proposals.

Ian Hudson, chief executive officer of the MHRA, said the responses to its consultation had “helped us prepare a robust plan to make sure our regulatory processes for medicines, clinical trials and medical devices are fit for purpose on exit day”.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20205971

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Injectable Drugs Guide

    Injectable Drugs Guide

    A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.

    £54.00Buy now
  • BNF for Children (BNFC) 2018-2019

    BNF for Children (BNFC) 2018-2019

    The BNFC contains essential practical information for all healthcare professionals involved in prescribing, dispensing, monitoring and administration of medicines to children.

    £57.50Buy now
  • Good Pharmacovigilance Practice Guide

    Good Pharmacovigilance Practice Guide

    An essential guide on pharmacovigilance of medicinal products for human use. Practical advice for developing effective pharmacovigilance systems.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.